VSIG4 Monoclonal Antibody (NLA14), PE, eBioscience™, Invitrogen™

Description

• Description: This NLA14 monoclonal antibody recognizes mouse V-Set and Immunoglobulin domain containing 4 (VSIG4), also known as Complement Receptor of the Immunoglobulin superfamily (CRIg) or Z39Ig
• VSIG4 is a type I transmembrane glycoprotein structurally related to the B7 family of immune regulatory proteins
• It contains one complete V-type Ig domain and one truncated C-type Ig domain
• VSIG4 is exclusively expressed on tissue resident and tumor infiltrating macrophages
• It has been shown to bind complement components C3b and iC3b
• This binding inhibits the alternative complement pathway and facilitates phagocytosis of complement-opsonized pathogens
• VSIG4 has also been reported to suppress T cell activation, proliferation and IL-2 production thereby playing a role in the maintece of peripheral T cell tolerance and suppression of established inflammation
• Expression of VSIG4 on tumor-infiltrating macrophages suggests its role in immune evasion
• Pro-inflammatory stimuli such as TNF and LPS have been reported to down-regulate the expression of VSIG4
• Peritoneal macrophages in Balb/c mice express significantly higher levels of VSIG4 than such macrophages in C57Bl/6 or Swiss Webster mice
• The NLA14 antibody will recognize VSIG4 on cells that have been formaldehyde-fixed and permeabilized
• This antibody does not block the ligation of VSIG4 to its T cell ligand
• The NLA14 antibody does not cross-react with rat or human VSIG4
• T cell activation by APCs is positively and negatively regulated by members of the B7 family
• VSIG4 is a strong negative regulator of murine and human T cell proliferation and IL-2 production.